Cancer Letters
Volume 225, Issue 1 , Pages 99-103, 8 July 2005

Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal cancer

Division of Cell Biology, Floor 9, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping SE-581 85, Sweden

Received 5 January 2005; received in revised form 5 February 2005; accepted 6 February 2005.

Abstract 

Previously, increased expression of nitric oxide synthase 2 (NOS2) in colorectal cancer (CRC) has been identified. The NOS2 gene is transcriptionally regulated, which suggests that polymorphisms in the NOS2 promoter may have a role for CRC development and progression. The genotyping was performed with PCR/RFLP, single strand conformation analysis or MegaBACE genotyping of normal blood DNA from CRC patients and normal healthy controls. However, no significant association between NOS2 polymorphisms and CRC onset or clinical outcome was evident. In conclusion, these results, therefore, suggest that NOS2 promoter polymorphisms have a limited effect on the onset or progression of CRC.

Keywords: NOS2, Nitric oxide, Colorectal cancer, Polymorphism, Promoter

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(05)00128-X

doi:10.1016/j.canlet.2005.02.006

Cancer Letters
Volume 225, Issue 1 , Pages 99-103, 8 July 2005

Article Tools